Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CALCRL | Q16602 | 2/20 | 0.51 |
| ▸ | SSTR3 | P32745 | 1/20 | 0.47 |
| ▸ | HRH1 | P35367 | 3/20 | 0.42 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.42 |
| ▸ | MMP3 | P08254 | 1/20 | 0.41 |
| ▸ | SIRT2 | Q8IXJ6 | 4/20 | 0.41 |
| ▸ | SIRT1 | Q96EB6 | 4/20 | 0.41 |
| ▸ | F2 | P00734 | 1/20 | 0.41 |
| ▸ | SIRT3 | Q9NTG7 | 2/20 | 0.40 |
| ▸ | FAP | Q12884 | 1/20 | 0.40 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.40 |
| ▸ | ECE1 | P42892 | 1/20 | 0.40 |
| ▸ | NPY1R | P25929 | 1/20 | 0.39 |
| ▸ | NPY2R | P49146 | 1/20 | 0.39 |
| ▸ | NPY4R | P50391 | 1/20 | 0.39 |
| ▸ | NPY5R | Q15761 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24829447 | 1.00 | CALCRL (0.51) | CALCRLSSTR3HRH1HDAC1MMP3 | |
| SCHEMBL22910386 | 0.93 | CALCRL (0.51) | CALCRLSSTR3HRH1HDAC1MMP3 | |
| SCHEMBL23347148 | 0.92 | CALCRL (0.48) | CALCRLSSTR3HRH1HDAC1MMP3 | |
| SCHEMBL24164777 | 0.92 | CALCRL (0.50) | CALCRLSSTR3HDAC1SIRT2SIRT1 | |
| SCHEMBL24829565 | 0.91 | CALCRL (0.49) | CALCRLSSTR3HRH1HDAC1MMP3 | |
| SCHEMBL27058431 | 0.91 | CALCRL (0.55) | CALCRLSSTR3HRH1F2NPY1R | |
| SCHEMBL23347260 | 0.89 | CALCRL (0.47) | CALCRLSSTR3HRH1HDAC1MMP3 | |
| SCHEMBL24829473 | 0.89 | SSTR3 (0.57) | CALCRLSSTR3SIRT2SIRT1SIRT3 | |
| SCHEMBL21065668 | 0.88 | FAP (0.42) | CALCRLSIRT2SIRT1SIRT3FAP | |
| SCHEMBL19709466 | 0.88 | FAP (0.42) | CALCRLSIRT2SIRT1SIRT3FAP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240218011-A1 | GLUCOCORTICOID RECEPTOR AGONISTS AND CONJUGATES THEREOF | FIREFLY BIO, INC. | 2024-07-04 | — | — | US | disclosed |
| US-20230062712-A1 | ANTI-ASGR1 ANTIBODY CONJUGATES AND USES THEREOF | SILVERBACK THERAPEUTICS, INC. | 2023-03-02 | — | — | US | disclosed |
| US-11541126-B1 | Anti-ASGR1 antibody TLR8 agonist comprising conjugates and uses thereof | SILVERBACK THERAPEUTICS, INC. (US) | 2023-01-03 | — | — | US | disclosed |
| US-20220362396-A1 | AMINO-PYRAZINECARBOXAMIDE COMPOUNDS, CONJUGATES, AND USES THEREOF | SILVERBACK THERAPEUTICS, INC. | 2022-11-17 | — | — | US | disclosed |
| US-20220169660-A1 | CYCLIC AMINO-PYRAZINECARBOXAMIDE COMPOUNDS AND USES THEREOF | SILVERBACK THERAPEUTICS INC (US) | 2022-06-02 | — | — | US | disclosed |
| WO-2022076905-A1 | ALK5 INHIBITORS, CONJUGATES, AND USES THEREOF | SILVERBACK THERAPEUTICS, INC. (US) | 2022-04-14 | — | — | WO | disclosed |
| WO-2022006327-A1 | ANTI-ASGR1 ANTIBODY CONJUGATES AND USES THEREOF | SILVERBACK THERAPEUTICS, INC. (US) | 2022-01-06 | — | — | WO | disclosed |
| US-20210139477-A1 | ALK5 INHIBITORS, CONJUGATES, AND USES THEREOF | SILVERBACK THERAPEUTICS, INC. | 2021-05-13 | — | — | US | disclosed |
| US-20210130473-A1 | TGFßR1 INHIBITOR-ASGR ANTIBODY CONJUGATES AND USES THEREOF | SILVERBACK THERAPEUTICS, INC. | 2021-05-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210139477-A1 | ALK5 INHIBITORS, CONJUGATES, AND USES THEREOF | ALK, ALKBH5, ACVR1 | CALCRL 4173/4885SSTR3 2097/4885HRH1 1637/4885 |
| US-20240218011-A1 | GLUCOCORTICOID RECEPTOR AGONISTS AND CONJUGATES THEREOF | NR3C1, NR3C2, MC2R | CALCRL 513/4885SSTR3 591/4885HRH1 601/4885 |
| US-20230062712-A1 | ANTI-ASGR1 ANTIBODY CONJUGATES AND USES THEREOF | ASGR1, HAVCR2, FCGR2A | CALCRL 2527/4885SSTR3 2212/4885HRH1 1623/4885 |
| US-20220362396-A1 | AMINO-PYRAZINECARBOXAMIDE COMPOUNDS, CONJUGATES, AND USES THEREOF | TGFBR2, SMAD2, ACVR2A | CALCRL 2775/4885SSTR3 498/4885HRH1 319/4885 |
| US-20210130473-A1 | TGFßR1 INHIBITOR-ASGR ANTIBODY CONJUGATES AND USES THEREOF | TGFBR2, ASGR1, TGFBR1 | CALCRL 2302/4885SSTR3 1350/4885HRH1 822/4885 |
| US-11541126-B1 | Anti-ASGR1 antibody TLR8 agonist comprising conjugates and uses thereof | ASGR1, TLR8, HAVCR2 | CALCRL 1791/4885SSTR3 1768/4885HRH1 889/4885 |
| US-20220169660-A1 | CYCLIC AMINO-PYRAZINECARBOXAMIDE COMPOUNDS AND USES THEREOF | TGFBR2, ACVR2A, SMAD2 | CALCRL 1162/4885SSTR3 563/4885HRH1 587/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.